Press release
Esophageal Cancer Clinical Trial Landscape Gains Momentum as 80+ Biopharma Players Advance Next-Generation Therapies | DelveInsight
Esophageal Cancer Clinical Trials
DelveInsight's latest report, "Esophageal Cancer Pipeline Insight 2026" offers an in-depth evaluation of the evolving therapeutic landscape, highlighting contributions from over 80 companies and more than 100 pipeline candidates targeting esophageal cancer. The report delivers a detailed overview of both clinical and preclinical drug profiles, along with comprehensive assessments based on product type, development phase, route of administration, and molecular classification. Additionally, it sheds light on discontinued and inactive programs within the space.
Discover the latest innovations in esophageal cancer research and stay informed about breakthrough developments in the pipeline: https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Key Highlights from the Esophageal Cancer Pipeline Report
* On February 20, 2026, SOFIE initiated a clinical study evaluating the effectiveness of [F]FAPI-74 PET/CT imaging for detecting metastatic disease in patients diagnosed with gastric, gastroesophageal junction, or esophageal cancers. Following standardized dosing and screening procedures, participants undergo PET/CT scans, with standard-of-care (SOC) interventions monitored for up to three months post-injection.
* On February 18, 2026, Merck Sharp & Dohme LLC launched a Phase I/II clinical trial to assess the safety and tolerability of investigational therapies combined with pembrolizumab and fluoropyrimidine-based chemotherapy. This study focuses on first-line treatment for patients with HER2-negative, locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.
* The report underscores a dynamic pipeline, with more than 80 active companies developing over 100 therapies aimed at improving outcomes in esophageal cancer.
* Prominent players in this domain include OncoTherapy Science/Shionogi & Co., Oncolys BioPharma, Lyvgen Biopharma, Adlai Nortye Biopharma, NovaRock Biotherapeutics, Genmab, Genentech, Jiangsu Hengrui Medicine, Taiho Pharmaceutical, Mirati Therapeutics, Boehringer Ingelheim, and several others.
* Notable therapies under investigation include Panitumumab, Capecitabine, Oxaliplatin, Ramucirumab, Paclitaxel, Pertuzumab, and Trastuzumab, among others.
Access the full clinical trials assessment and stay updated with the latest advancements in cancer care : https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Emerging Drug Profiles in Esophageal Cancer
S-588410 (OncoTherapy Science / Shionogi & Co.)
S-588410 is a peptide-based cancer vaccine originally developed by OncoTherapy Science and later licensed to Shionogi. This subunit vaccine is administered subcutaneously and consists of a combination of peptide epitopes derived from tumor-associated antigens targeting HLA-A*2402. Designed as a novel molecular entity, it is currently in Phase III clinical trials for esophageal cancer.
Telomelysin (OBP-301) - Oncolys BioPharma Inc
Telomelysin is a genetically engineered oncolytic adenovirus that selectively replicates in cancer cells using the hTERT promoter. Early clinical findings in melanoma demonstrated systemic anti-tumor effects, including regression of both injected and non-injected tumors. The therapy enhances immune cell infiltration while reducing regulatory T cells. It is currently being evaluated in Phase II trials for esophageal cancer.
LVGN-6051 - Lyvgen Biopharma
LVGN-6051 is an innovative monoclonal antibody targeting the 4-1BB (CD137) pathway. Engineered to activate immune responses specifically within the tumor microenvironment, it balances efficacy and safety by engaging FcRIIB-expressing immune cells. This therapy is currently in Phase I development.
AN-0025 - Adlai Nortye Biopharma
AN-0025 is a small molecule EP4 receptor antagonist designed to modulate the tumor microenvironment. Originally discovered by Eisai, it has shown promising results in combination with radiation therapy, achieving significant response rates in early trials. The drug is currently being explored in Phase I studies for esophageal cancer.
Download free sample report now : https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Comprehensive Insights Offered by the Report
* Detailed profiling of companies engaged in esophageal cancer drug development, along with their respective pipelines
* Categorization of therapies based on development stages: early, mid, and late-stage
* Analysis of both active and discontinued research programs
* Evaluation of pipeline drugs by mechanism of action, molecular type, route of administration, and therapeutic approach (monotherapy vs. combination)
* Insights into strategic collaborations, licensing agreements, and funding activities shaping the future of the market
Explore the report to uncover unmet needs and emerging opportunities in esophageal cancer treatment : https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Esophageal Cancer Therapeutic Segmentation
Esophageal Cancer By Route of Administration:
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
Esophageal Cancer By Molecule Type:
* Monoclonal antibodies
* Small molecules
* Peptides
Esophageal Cancer Report Scope
* Global coverage of the esophageal cancer pipeline landscape
* Therapeutic evaluation based on product type (monotherapy, combination, or both)
* Analysis across development stages: Discovery, Preclinical, Phase I, Phase II, and Phase III
* Coverage of major Esophageal Cancer companies including BeiGene, AstraZeneca, Amgen, Pfizer, Novartis, Eli Lilly, Adaptimmune, Innovent Biologics, Janssen Pharmaceuticals, Merck KGaA, and many others
* Detailed review of key therapies such as Panitumumab, Capecitabine, Oxaliplatin, Ramucirumab, Paclitaxel, Pertuzumab, and Trastuzumab
Gain strategic insights into market drivers, barriers, and future growth opportunities by accessing the full report : https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Contents
* Introduction
* Executive Summary
* Disease Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Analytical Perspective
* Late-Stage (Phase III) Candidates
* Mid-Stage (Phase II) Candidates
* Early-Stage (Phase I) Candidates
* Preclinical and Discovery Programs
* Inactive Products
* Key Companies and Therapies
* Unmet Needs
* Market Drivers and Barriers
* Future Outlook and Analyst Insights
* Appendix
About DelveInsight
DelveInsight is a globally recognized healthcare market research and consulting firm specializing in delivering actionable insights across the life sciences sector. With a team of experienced analysts and domain experts, the company provides high-quality, data-driven intelligence to support strategic decision-making. DelveInsight's customized solutions empower clients to stay competitive and capitalize on emerging opportunities in the rapidly evolving healthcare landscape.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=esophageal-cancer-clinical-trial-landscape-gains-momentum-as-80-biopharma-players-advance-nextgeneration-therapies-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Esophageal Cancer Clinical Trial Landscape Gains Momentum as 80+ Biopharma Players Advance Next-Generation Therapies | DelveInsight here
News-ID: 4431958 • Views: …
More Releases from ABNewswire
Hepatocellular Carcinoma Drug Development Landscape Gains Momentum with Over 90 …
Leading Hepatocellular Carcinoma companies involved in this space include Can-Fite BioPharma, Surface Oncology, Novartis Oncology, GlaxoSmithKline, CStone Pharmaceuticals, Chugai Pharmaceutical, and several others.
DelveInsight's latest report, "Hepatocellular Carcinoma Pipeline Insight 2026 [https://www.delveinsight.com/sample-request/hepatic-tumor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]," offers an extensive evaluation of the evolving therapeutic landscape, highlighting the contributions of more than 90 pharmaceutical and biotechnology companies and over 95 investigational drugs targeting hepatocellular carcinoma (Hepatoc. The report delivers detailed profiles of pipeline candidates across both…
Hemophilia Clinical Development Landscape Strengthens as 80+ Companies Drive Inn …
Prominent Hemophilia companies include Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk, and others.
DelveInsight's latest report, "Hemophilia Pipeline Insight, 2026" offers a detailed evaluation of the evolving Hemophilia pipeline, highlighting the contributions of more than 80 companies and over 80 investigational therapies. The report presents an extensive overview of pipeline drug candidates across both clinical and…
Head and Neck Cancer Clinical Pipeline Accelerates: Over 80 Companies Advancing …
Major Head and Neck Cancer companies driving innovation include Merus, Bicara Therapeutics, Kura Oncology, Theriva Biologics, Nykode Therapeutics, Cue Biopharma, BioNTech, Exelixis, AstraZeneca, Johnson & Johnson, AbbVie, Iovance Biotherapeutics, Immutep, Pyxis Oncology, ALX Oncology, iTeos Therapeutics, and several others.
DelveInsight's latest report, "Head and Neck Cancer Pipeline Insight 2026 [https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]" delivers an extensive evaluation of the evolving therapeutic landscape, highlighting the involvement of more than 80 pharmaceutical and biotechnology companies working…
Muscle Invasive Bladder Cancer Market Set for Strong Growth Through 2034, Driven …
The Muscle Invasive Bladder Cancer (MIBC) treatment landscape is undergoing rapid transformation, fueled by an expanding pipeline and active participation from leading pharmaceutical and biotechnology companies such as CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics, Binhui Biopharmaceutical, AstraZeneca, ImmunityBio, Inc., and Bristol Myers Squibb, among others.
DelveInsight's report, "Muscle Invasive Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2034," provides a comprehensive evaluation of disease epidemiology, current…
More Releases for Esophageal
Rising Prevalence Of Chronic Esophageal Disorders Boosts The Esophageal Catheter …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Esophageal Catheters Market Size By 2025?
The market for esophageal catheters has experienced significant expansion recently. Its growth is projected to continue from a market size of $2.43 billion in 2024 to an increased value of $2.64 billion in 2025, reflecting a compound annual growth…
Evolving Market Trends In The Esophageal Dilator Industry: Advanced Solutions En …
The Esophageal Dilator Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Esophageal Dilator Market Size During the Forecast Period?
The esophageal dilator market size will grow from $1.49 billion in 2024 to $1.57 billion in 2025 at a CAGR of 5.2%. Growth…
Evolving Market Trends In The Esophageal Dysphagia Industry: Innovative Technolo …
The Esophageal Dysphagia Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Esophageal Dysphagia Market Size During the Forecast Period?
The market size for esophageal dysphagia has seen robust growth in the past few years. Projections show that it is set to expand…
Key Trend Reshaping the Esophageal Dilator Market in 2025: Advanced Solutions En …
What combination of drivers is leading to accelerated growth in the esophageal dilator market?
The esophageal dilator market is expected to see growth driven by the increasing occurrence of esophageal disorders. These disorders refer to a range of conditions affecting the esophagus, responsible for transporting food and fluids from the mouth to the stomach. The escalated prevalence of such disorders can be linked to factors such as the growing instances of…
Advanced Solutions Enhanced Esophageal Dilator Market Trend: A Crucial Influence …
What Is the Expected Size and Growth Rate of the Esophageal Dilator Market?
The market size for esophageal dilators has experienced robust growth in the past few years. The market's value, estimated at $1.49 billion in 2024, is predicted to inflate to $1.57 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.2%. This positive trend during the historical period is primarily driven by factors such as an increase…
Top Factor Driving Esophageal Catheters Market Growth in 2025: Rising Prevalence …
How Big Is the Esophageal Catheters Market Expected to Be, and What Will Its Growth Rate Be?
The esophageal catheters market has experienced significant growth in recent years. It will grow from $2.43 billion in 2024 to $2.64 billion in 2025, at a CAGR of 8.6%. The growth can be attributed to advancements in critical care, the rise of cardiac and respiratory disorders, the use of minimally invasive procedures, and developments…
